Mode
Text Size
Log in / Sign up
Phase 4 Completed N=16 Randomized Triple-blind Treatment

Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

Source: ClinicalTrials.gov NCT02330094 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcomePrimary: Average Numeric Pain Score — 5.2; 5.8 score on a scale — p=0.7
◆ Published Evidence
Established
20citations · ~3 / year
Safety, Tolerability, and Efficacy of Pain Reduction by Gabapentin for Acute Headache and Meningismus After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
Frontiers in neurology · 2020 · Open access · Likely link

Summary

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.

Linked Publications

  • Safety, Tolerability, and Efficacy of Pain Reduction by Gabapentin for Acute Headache and Meningismus After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
    Frontiers in neurology · 2020 · 20 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Numeric Pain Score
5.2; 5.8 0.7
PRIMARY
Average Narcotic Consumption
19.4; 20.2 0.79
SECONDARY
Pain Control Satisfaction Questionnaire
14; 12.6 0.66

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Have aneurysmal subarachnoid hemorrhage (aSAH) diagnosed by CT scan of the brain and/or angiogram evidence of intracranial aneurysm (CTA or digital subtraction angiogram or MRA)
  • Have symptomatic headache
  • Able to swallow and verbalize pain score
  • No known allergy to gabapentin or fentanyl
  • Numeric pain score ≥ 5
  • Ability to provide written personal consent

Exclusion Criteria

  • Gabapentin use prior to SAH admission
  • Renal failure with creatinine clearance less than 30 mL/min
  • Unable to receive standard of care pain medications
  • Pregnant or breastfeeding patients
  • History of severe depression defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02330094) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search